Previous 10 | Next 10 |
LOS ANGELES, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, will release its financial resul...
Protagonist Therapeutics (NASDAQ:PTGX) +89% after FDA removes clinical hold on rusfertide program Flexion Therapeutics (NASDAQ:FLXN) +73% Pacira Therapeutics acquires Flexion Therapeutics for $8.50 per share in cash plus one CVR Adamas Pharmaceuticals (NASDAQ:ADMS) +7...
Gainers: Red Cat (OTCQB:RCAT) +46%. AerSale (NASDAQ:ASLEW) +38%. Keros (NASDAQ:KROS) +28%. Camber Energy (NYSE:CEI) +27%. Puhui Wealth Investment Management (NASDAQ:PHCF) +27%. ENGlobal (NASDAQ:ENG) +25%. Paltalk (NASDAQ:PALT) +25%. Aemetis (NASDAQ:AMTX) +20%. Southwestern (NYSE:SWN) +19%. Ne...
Gainers: Cellect Biotechnology (NASDAQ:APOP) +24%, Keros Therapeutics (NASDAQ:KROS) +24%, Gossamer Bio (NASDAQ:GOSS) +17%, Seelos Therapeutics (NASDAQ:SEEL) +16%, DiaMedica Therapeutics (NASDAQ:DMAC) +9%. Losers: ASLAN Pharmaceuticals (NASDAQ:ASLN)...
On May 13, 2020, "Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002". On Sept 24, 2021, "Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients w...
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +68%, Pieris Pharmaceuticals (NASDAQ:PIRS) +11%, Molecular Templates (NASDAQ:MTEM) +11%, Paratek Pharmaceuticals (NASDAQ:PRTK) +9%, Capricor Therapeutics CAPR +4%. Losers: Kintara Therapeutics KTRA -19%, Oncon...
ZIVO Bioscience (NASDAQ:ZIVO) +81%. Meredith Corporation (NYSE:MDP) +16% on report IAC is in purchase talks Capricor Therapeutics (NASDAQ:CAPR) +26% on positive CAP-1002 data from mid-stage duchenne muscular dystrophy study vTv Therapeutics (NASDAQ:VTVT) +21% on ascending dose study...
–Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)– –Additional Positive Endpoints of Full PUL v2.0 (p=0.04) and Cardiac Endpoint of Ejection Fraction (p=0.002)– – One-Yea...
- Cantor Fitzgerald Virtual Global Healthcare Conference: September 30 - - The Cell & Gene Meeting on the Mesa Annual Conference: October 13 - LOS ANGELES, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) (“Capricor” or ...
Are Biotech Penny Stocks On Your Watch List This Week? Penny stocks are well known for their volatility swings. Whether we’re talking about stocks with insider trading, meme stocks, or penny stocks with high analyst ratings, there are myriad catalysts to seek out. However, sp...
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000 ® Index an...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted ...